IFRX InflaRx N.V.
Price Chart
Executive Summary
InflaRx reported financial results for 2025, highlighted by a narrow improvement in net loss to €45.6M from €46.1M in 2024, alongside strong Phase 2a data for izicopan in hidradenitis suppurativa and chronic spontaneous urticaria. The company is pivoting to focus on izicopan as a 'pipeline-in-a-product' while scaling back GOHIBIC commercial activities, preserving €46.2M in cash to fund operations into mid-2027.
Key Financial Metrics
Actionable Insight
The strong Phase 2a data and strategic refocus on izicopan suggest upcoming catalysts in HS and potentially AAV; watch for Phase 2b trial design clarity from FDA and partnership signals. The extended cash runway reduces near-term dilution risk.
Key Facts
- Positive Phase 2a data for izicopan in HS and CSU showed rapid, meaningful clinical improvements with no safety concerns.
- Company is focusing entirely on izicopan, discontinuing GOHIBIC commercial spending in the U.S. and writing down €4.0M in inventory.
- Net loss improved to €45.6M in 2025 from €46.1M in 2024; R&D expenses dropped 27% YoY to €25.7M.
- Cash, cash equivalents, and marketable securities totaled €46.2M as of December 31, 2025, funding operations into mid-2027.
- Plans for a PK bridging study in China and a virtual Capital Markets Day this spring to detail izicopan's development path.
Financial Impact
Reduced R&D and commercial spending led to lower net loss and improved cash efficiency; €33.3M raised via financing in 2025.
Risk Factors
- izicopan remains in early development; Phase 2b and later trials may not replicate Phase 2a results.
- Heavy reliance on a single asset (izicopan) increases binary risk.
- Market cap of $52M may not fully reflect development risk in a highly competitive immunology space.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258900 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 6, 2026
4w ago
|
424B5
| $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.71 (+35.47%) |
|
May 6, 2026
4w ago
|
6-K
| $2.50 $2.06 | ▼ −17.60% | ▼ −20.38% | $1.71 (−31.60%) |
|
May 6, 2026
4w ago
|
Press Release
| $2.50 $2.06 | ▼ −17.60% | ▼ −20.38% | $1.71 (−31.60%) |
|
May 6, 2026
4w ago
|
6-K
| $2.50 $2.06 | ▼ −17.60% | ▼ −20.38% | $1.71 (−31.60%) |
|
May 4, 2026
5w ago
|
6-K
| $1.97 $2.17 | ▲ +10.15% | ▲ +5.20% | $1.71 (−13.20%) |
|
May 1, 2026
5w ago
|
Press Release
| $2.10 $2.28 | ▲ +8.57% | ▲ +3.29% | $1.71 (−18.57%) |
|
Apr 23, 2026
6w ago
|
6-K
| $1.48 $2.47 | ▲ +66.89% | ▲ +62.87% | $1.71 (+15.54%) |
|
Apr 9, 2026
8w ago
|
Press Release
| $1.03 $2.50 | ▲ +142.72% | ▲ +135.15% | $1.71 (+66.02%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $0.9100 $1.59 | ▲ +74.73% | ▲ +67.10% | $1.71 (+87.91%) |
|
Mar 18, 2026
11w ago
|
Press Release
| $0.8800 $1.20 | ▲ +36.36% | ▲ +30.32% | $1.71 (+94.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access